688443 Chongqing Genrix Biopharmaceutical
- 22.36
- -0.59-2.57%
Chongqing Genrix Biopharmaceutical News
Zhixiang Jintai (688443.SH): 25 million shares of restricted shares will be unlocked on September 27th.
On September 19, Gelonghui announced that the total number of stocks listed this time for Zhixiang Jintai (688443.SH) is 25 million shares. The listing date for stocks is September 27, 2024.
Chongqing Genrix Biopharmaceutical Chair Proposes Up to 40-Million-Yuan Share Buyback
Express News | Zhi Xiang Jin Tai: The chairman proposed to repurchase shares in the range of 20 million yuan to 40 million yuan.
Zhixiang Jintai (688443): Selliteqi monoclonal antibody approved for listing, core products progressing smoothly.
2024 first-half performance: Sartuzumab vedotin was approved in August 2024, and the company had no main business income in the first half of 2024, only a small amount of other business income of 0.0127 million yuan from land leasing; sales expenses 3697.
Zhi Xiang Jin Tai (688443): Commercialization of IL-17 is underway, and the research pipeline is steadily progressing.
Report Summary: IL-17 monoclonal antibody has recently been approved for marketing, officially starting commercialization and actively promoting access and market expansion. It is expected to empower early commercialization, with a rich pipeline of research and continuous efficient clinical progress, promising long-term performance growth. Investment
2024 Semi-Annual Report Summary
2024 Semi-Annual Report
Zhixiang Jintai (688443.SH) released its performance for the first half of the year, with a net loss of 0.362 billion yuan.
Zhixiang Jintai (688443.SH) released the 2024 interim report, with a revenue of 1...
Express News | Just two days after being approved for listing, the first dose of the new drug Sai Li Qi monoclonal antibody injection by ZhiXiang Jintai has been administered.
Genrix Biopharmaceutical's Celecoxib Injection Gets Nod to Be Registered; Shares Drop 4%
First approved product on the market, Zhixiang Jintai (688443.SH): The use of Saliq monoclonal antibody for the treatment of moderate to severe plaque psoriasis.
Zhixiang Jintai (688443.SH) announced that today, the company received the "Pharmaceutical..." issued by the National Medical Products Administration.
Express News | ZhiXiang JinTai: GR1802 injection is approved for clinical trials for the indication of atopic dermatitis in children and adolescents.
Express News | Star market closing review: Star 50 index fluctuated and closed up 0.03%. The medical instruments sector continued to decline.
Express News | Zhixiang Jintai: Launches Phase III Clinical Trial of GR2001 Injection.
A-share biological products continue to decline, Kangleweishi falls nearly 7%.
On August 14th, Gelunhui reported that Kang Le Wei Shi fell nearly 7%, and Zhixiang Jintai, Baipusaisi, Baikeshengwu, Beijing Wantai Biological Pharmacy Enterprise, Chongqing Zhifei Biological Products followed suit.
Haitong Int'l: Immune therapy has a broad market space, and the clinical value of TCE dual-antibodies is prominent.
With the development and maturity of TCE dual antibody technology, more domestic enterprises will choose to layout TCE dual antibody in order to enter the race track of solid tumors and self-immunity areas. TCE dual antibody has the potential to become the next investment trend in the field of immunotherapy.
Express News | Zhixiang Jintai: GR1803 injection is included in the list of breakthrough therapeutic varieties.
Express News | Star Market closing review: Orthopedic material concept stock, Ausin Medical, rose by the daily limit, while most semiconductor sector stocks fell.
Zhi Xiang Jintai (688443): Self-immune layout is multi-dimensional, and dual-anti-platform is gradually realized.
We believe that the company's core products are entering a period of rapid realization. The company is deeply cultivating the self-immune area, laying out multiple innovative products targeting IL-17A, IL-4R, TSLP and other targets, and developing the dual antibody platform GR1801 and GR1803.
Express News | Zhixiang Jintai: GR1802 injection has initiated Phase III clinical trial.
Analysis
Price Target
No Data
No Data